Clinical Research Directory

Inclusion Criteria: 1. Voluntarily participate in the clinical trial; fully understand and be informed about this study and sign the informed consent form; 2. At the time of screening, the age should be between 18 and 75 years old (inclusive), regardless of gender; 3. Patients with histologically confirmed stage IIIA NSCLC (T4N0M0, T3-4N1M0, T1a-2bN2M0) who underwent R0 resection and received postoperative adjuvant chemotherapy (Exclusion of EGFR sensitizing mutations and ALK fusion); and who received the first dose of PANK-003 cell injection combined with postoperative adjuvant chemotherapy within 8 weeks after radical surgery.; 4. At the time of enrollment, the expected survival time is more than 6 Months; 5. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1; 6. At the time of screening, the laboratory tests should meet the following requirements: * White blood cell count ≥ 3.0×10⁹/L; * Neutrophil count ≥ 1.5×10⁹/L; * Lymphocyte count ≥ 0.5×10⁹/L; * Hemoglobin ≥ 90 g/L; * Platelets ≥ 75×10⁹/L; * Serum total bilirubin ≤ 2.0 × ULN (Upper Limit of Normal); for patients with a history/suspected Gilbert's syndrome, total bilirubin (TBIL) must be ≤ 3 × ULN. * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN; * Creatinine \< 1.5×ULN and endogenous creatinine clearance rate ≥ 50 mL/minute (Cockcroft-Gault method for calculating creatinine clearance rate: For men, creatinine clearance rate = \[(140 - age) × body weight (kg)\] / \[0.818 × creatinine (μmol/L)\]; For women, creatinine clearance rate = \[(140 - age) × body weight (kg) × 0.85\] / \[0.818 × creatinine (μmol/L)\]). 7. Female subjects of childbearing potential must have a negative serum pregnancy test at screening and be willing to use medically recognized highly effective contraception during the study and for at least 1 year after the last study treatment; male subjects with partners of childbearing potential must have undergone surgical sterilization or agree to use effective contraception during the study and for at least 1 year after the last study treatment; 8. Investigator-confirmed eligibility for study enrollment. Exclusion Criteria: 1. NSCLC patients who have received neoadjuvant therapy; 2. Pregnant or lactating women; 3. History of other malignancies, except: * Cured non-melanoma skin cancer * Carcinoma in situ of the cervix * Localized prostate cancer * Superficial bladder cancer * Other malignancies with disease-free survival \>5 years; 4. Positive virology serology meeting any of: * HBsAg(+) and/or HBeAg(+) with HBe-Ab(+) and/or HBc-Ab(+) and HBV-DNA \> lower limit of quantification * HCV-Ab(+) * TP-Ab(+) * HIV-Ab(+); 5. Received investigational drugs or other cell-based immunotherapy within 28 days before screening; 6. Administration of live/attenuated vaccines within 4 weeks prior to NK cell infusion; 7. Medical conditions requiring systemic corticosteroid therapy or other immunosuppressive drug treatments during the study period as determined by the investigator; 8. Hypersensitivity to: * Any component of NK cell products (including serum albumin) * Common emergency medications or anesthetics; 9. Unstable cardiovascular diseases within 180 days pre-screening, including: * Unstable angina * Myocardial infarction * Heart failure (NYHA class ≥III) * Severe arrhythmia requiring medication * Cardiac angioplasty, coronary stenting, or CABG; 10. Any condition that may compromise protocol compliance or patient safety as determined by the investigator: * Poorly controlled diabetes * Uncontrolled infections * Central nervous system disorders * Bleeding/thrombotic diathesis * Poor compliance * Substance abuse.